Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

35 Pages (Click to Jump) V  « < 30 31 32 33 34 35 >   
 
  
Reply to this topic

ANP, ANTISENSE THERAPEUTICS LIMITED
smjam
post Posted: Jan 19 2005, 02:37 PM
  Quote Post


Posts: 55


100 day exp moving average crossing over 200 dayexp ma. Alsobroken above SAR.

 
smjam
post Posted: Jan 9 2005, 09:45 PM
  Quote Post


Posts: 55


In reply to: edsel on Friday 07/01/05 11:46am

It appears to have broken out from that range on Friday and has been moving in a bullish direction since the low on 18 Oct. There have been some positive announcements lately that the MS drug is progressing positively at this stage.

I hold smile.gif



 
edsel
post Posted: Jan 7 2005, 11:46 AM
  Quote Post


Posts: 92
Thanks: 1


If it breaks out of its trading box of 11 to 13.5 cents, we could see a new box form in the 14 to maybe 17 cent range for a while.

 
edsel
post Posted: Jan 7 2005, 11:40 AM
  Quote Post


Posts: 92
Thanks: 1


Bit of interest starting to form in this stock, early days yet, could be forthcoming adr listing.

Disclosure- I am a holder.

 
smjam
post Posted: Nov 1 2004, 10:19 AM
  Quote Post


Posts: 55


thanks for the reply John,
It has been very quiet, hopefully .11 is support and there is some upward movement
with the presentation in NY and the ADR giving greater access for american investors.

smjam

 
john constantine
post Posted: Oct 31 2004, 10:41 PM
  Quote Post


Posts: 230
Thanks: 2


holding anpo after stagging out the fully paids for the free ride------eyes glaze over when my subscription copy of 'new scientist' tries to get into antisense tech,just worried that it may be bypassed by the next good thing,if antisense tech hasn't worked miricles yet.

 


smjam
post Posted: Oct 21 2004, 06:31 PM
  Quote Post


Posts: 55


smile.gif Melbourne, Australia ­ October 21, 2004 ­ Antisense Therapeutics Limited (ASX: ANP)
today announced that company management will present at the Rodman & Renshaw 6thAnnual Healthcare Conference at The Waldorf-Astoria Hotel in New York City on Wednesday, October 27,
2004 at 11:50 AM ET.

Mark Diamond, chief executive officer, is scheduled to present to an audience of analysts and portfolio
managers. His presentation will include both a company presentation and a moderated discussion
between management and institutional investors.



 
smjam
post Posted: Oct 18 2004, 09:00 PM
  Quote Post


Posts: 55


smile.gif Antisense Therapeutics is pleased to announce that it has accepted a proposal from The Bank of New
York to establish a Level 1 American Depository Receipt (ADR) program.

The establishment of this ADR program will facilitate the purchase of Antisense Therapeutics shares
by United States investors.

This initiative is a logical extension of the Company's focus on its international development, and an
appropriate vehicle to leverage the high awareness of and regard for antisense technology generally
and the growing international interest in Antisense Therapeutics' product development plans
specifically.

Mark Diamond, CEO of Antisense commented: "We are very excited to take this initial step in
bringing the Antisense story to international investors. A vital part of our long-term strategy to
enhance shareholder value is to improve liquidity and broaden and diversify our shareholder base by
enhancing the Company's visibility in the world's largest capital market. The ADR program will help
us capitalize on landmark achievements by making investing easier for existing and potential US
investors."


About ADRs
ADRs are commonly used to facilitate US investors investing in foreign companies not listed in the
USA. An ADR is created when a broker purchases a company's shares on the home stock market and
delivers those to the depositary's local custodian bank, which then instructs the depositary bank, The
Bank of New York, to issue Depositary Receipts. Depositary receipts may trade freely, just like any
other security, in the over-the-counter (OTC) market.

About Antisense Therapeutics Limited
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug
discovery and development company. ANP's mission is to create, develop and commercialise novel
antisense pharmaceuticals for large unmet markets. Its two most advanced projects target Multiple
Sclerosis (ATL1102), and Psoriasis (ATL1101). ANP plans to commercialise its pipeline via licensing/collaboration agreements with major
biotechnology and pharmaceutical companies. ANP's major shareholders include Circadian Technologies Limited (ASX: CIR), Isis Pharmaceuticals
Inc (NASDAQ: ISIS) and Queensland Investment Corporation. smile.gif


 
smjam
post Posted: Jun 26 2004, 03:29 PM
  Quote Post


Posts: 55


Positive move up 2c from 12 c base. MACD and volume improving. I hope it gets through 17c resistance soon. rolleyes.gif

 
awol
post Posted: Jun 9 2004, 10:22 AM
  Quote Post


Posts: 716


positive results from alt1102 /phase 1--announced after market yesterday
surprised a bit that volume traded isn't higher

 
 


35 Pages (Click to Jump) V  « < 30 31 32 33 34 35 >

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING